This suggests that EGFR-mutant lung cancers retain sensitivity to EGFR-TKIs upon retreatment; subsequent targeted therapy after failure of adjuvant targeted therapy may provide longer OS and may be a better sequential treatment model for patients with resected EGFR mutation NSCLC. This evidence concerns the gene EGFR and lung carcinoma.